Table 3 Sensitivity, Specificity, and Accuracy of predicting omalizumab response using cutoffs defined by the top cytokine or ratios.

From: Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

*Measures used in cutoff

Sensitivity

Specificity

Accuracy

AUC

Optimal CXCL10

0.57

1.00

0.86

0.63

Optimal CXCL10/IL-21

0.57

0.93

0.81

0.65

Optimal CXCL10/CCL17

0.71

0.79

0.76

0.77

IgE ≥ 100 + CXCL10

0.43

1.00

0.81

0.66

Optimal CXCL10/IL-13

0.43

1.00

0.81

0.64

Optimal CXCL10/IL-4

0.43

1.00

0.81

0.59

Optimal CXCL10/IL-17B

0.43

1.00

0.81

0.61

IgE ≥ 100 + CXCL10/IL-21

0.43

0.93

0.76

0.66

IgE ≥ 100 + CXCL10/IL-13

0.29

1.00

0.76

0.66

IgE ≥ 100 + CXCL10/IL-4

0.29

1.00

0.76

0.62

IgE ≥ 100 + CXCL10/IL-17B

0.29

1.00

0.76

0.64

IgE ≥ 100

0.57

0.64

0.62

0.61

IgE ≥ 100 + CXCL10/CCL17

0.29

0.93

0.71

0.62

  1. *IgE: total immunoglobulin E in ku/L at baseline; ‘Optimal’: using the cut-off point for the cytokine or ratio that maximizes predictive accuracy.
Back to article page